JAN (NYSE:JAN) Stock Price Target Lowered at Barclays

JAN (NYSE:JAN) had its price objective lowered by investment analysts at Barclays from $34.00 to $33.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s target price points to a potential upside of 14.10% from the company’s current price.

Other research analysts also recently issued research reports about the company. Morgan Stanley lifted their price target on JAN from $28.00 to $31.00 and gave the company an “overweight” rating in a report on Tuesday, August 18th. Wells Fargo & Company raised their price objective on JAN from $33.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 1st. Weiss Ratings initiated coverage on JAN in a research report on Thursday, August 6th. They set a “hold (c-)” rating for the company. Jefferies Financial Group began coverage on JAN in a research note on Tuesday, September 15th. They set a “buy” rating and a $36.00 target price on the stock. Finally, Raymond James Financial assumed coverage on JAN in a report on Tuesday, June 16th. They issued a “strong-buy” rating and a $34.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, JAN currently has an average rating of “Moderate Buy” and a consensus price target of $32.38.

JAN Trading Up 0.7%

NYSE JAN traded up $0.19 on Tuesday, hitting $28.92. 186,235 shares of the stock were exchanged, compared to its average volume of 1,471,221. JAN has a 52-week low of $22.76 and a 52-week high of $32.83. The company’s 50-day moving average price is $30.14 and its two-hundred day moving average price is $28.00.

JAN (NYSE:JAN) last released its earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The firm had revenue of $216.46 million during the quarter, compared to the consensus estimate of $203.32 million. The firm’s revenue for the quarter was up 45.4% on a year-over-year basis. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. Equities analysts anticipate that JAN will post 0.97 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. WINTON GROUP Ltd bought a new position in JAN during the second quarter valued at approximately $2,985,000. Engineers Gate Manager LP bought a new position in JAN during the second quarter valued at about $15,274,000. Greenland Capital Management LP bought a new position in JAN during the second quarter valued at about $575,000. Readystate Asset Management LP acquired a new stake in shares of JAN in the second quarter worth about $1,724,000. Finally, Wellington Management Group LLP acquired a new stake in shares of JAN in the second quarter worth about $8,739,000. Hedge funds and other institutional investors own 6.27% of the company’s stock.

JAN News Roundup

Here are the key news stories impacting JAN this week:

• Neutral Sentiment: The AGM announcement is primarily administrative and gives investors an opportunity to engage with management, but it does not disclose new financial results, guidance changes, contracts, or strategic developments likely to materially affect valuation. Janison Sets Hybrid 2026 AGM, Emphasises Shareholder Participation
• Negative Sentiment: Investor attention remains likely to center on Janison’s underlying performance: its latest quarter exceeded revenue expectations and revenue grew strongly year over year, but earnings per share missed consensus estimates. The company’s ability to meet its fiscal 2026 EPS guidance will be more important for the stock than the AGM logistics.

About JAN

JanOne Inc (NYSE: JAN) is a publicly traded company focused on addressing the opioid crisis through the development and commercialization of solutions intended to improve the treatment and prevention of opioid use disorder. The company has described its mission as combining business, technology and scientific initiatives to help reduce opioid-related harm.

JanOne’s activities have included biotechnology and pharmaceutical-development initiatives, as well as investments in technologies and businesses connected with healthcare and financial services.